Industry support of CME fell 14% in 2008, ACCME data show

Share this article:
Total commercial support of accredited CME dropped 14% to $1 billion in 2008, according to the Accreditation Council for Continuing Medical Education's annual report – even as the number of physicians participating in CME activities jumped 22% to 10.6 million.

For 2007, ACCME data showed commercial support leveling off, growing a meager 1% after a decade of substantial gains. In 1998, total commercial support was just $301 million.

Total income reported by accredited providers fell 6.8% to $2.3 billion in 2008, while total expenses rose 1.6% to $1.9 billion as providers incorporated new transparency and measurement policies.

While the total number of accredited CME activities fell 10% in 2008, to 100,898, the number of hours of CME logged rose 4% to 769,439. The number of non-physician participants also rose, from 5.1 million to 6.5 million, bringing the total number of all participants to 17 million.

Industry grants, accounting for 56% of CME funding, have been battered by across-the-board budget cuts at drug and device companies, along with intense scrutiny on commercial support of CME due to perceived bias.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...